ACA
ARKG icon

Ascension Capital Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Ascension Capital Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4,580
Closed -$292K – 32
2020
Q3 		$292K Buy
4,580
+226
+5% +$13.2K 0.23% 30
2020
Q2 		$227K Buy
+4,354
New +$187K 0.2% 34

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
MCM
Mainstay Capital Management Grand Blanc, Michigan $1.35B AUM 46.51% 1-Year Est. Return
CAN
Claraphi Advisory Network Aliso Viejo, United States $251M AUM 9.29% 1-Year Est. Return

Ascension Capital Advisors's ARKG Position: Q4 2020 in Review

Ascension Capital Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2020, closing a stake of 4,580 shares — an estimated $292K sold.

Ascension Capital Advisors first reported a position in ARKG in Q2 2020 and held it in 2 quarters. The position peaked at $292K in Q3 2020. 415 funds tracked by Wall St. Rank hold ARKG as of Q4 2020.

  • Ascension Capital Advisors reported no remaining ARK Genomic Revolution ETF position as of Q4 2020 after selling out during the quarter.
  • Ascension Capital Advisors sold 4,580 ARK Genomic Revolution ETF shares in Q4 2020, an estimated $292K.
  • Ascension Capital Advisors first reported a position in ARK Genomic Revolution ETF in Q2 2020 and held it in 2 quarters.
  • Ascension Capital Advisors's ARK Genomic Revolution ETF position peaked at $292K in Q3 2020.
  • 415 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2020.

Based on Ascension Capital Advisors's 13F filing for Q4 2020, filed 17 Feb 2021.